BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) issued an update on its FY 2024 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 3.100-3.250 for the period, compared to the consensus estimate of 2.040. The company issued revenue guidance of $2.8 billion-$2.8 billion, compared to the consensus revenue estimate of $2.8 billion.
BioMarin Pharmaceutical Price Performance
NASDAQ BMRN opened at $69.02 on Thursday. BioMarin Pharmaceutical has a 1 year low of $67.75 and a 1 year high of $99.56. The business’s fifty day moving average is $84.93 and its two-hundred day moving average is $84.02. The stock has a market capitalization of $13.11 billion, a P/E ratio of 64.51, a P/E/G ratio of 0.80 and a beta of 0.32. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.95 and a current ratio of 3.05.
BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) last issued its earnings results on Monday, August 5th. The biotechnology company reported $0.77 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.38 by $0.39. BioMarin Pharmaceutical had a return on equity of 6.91% and a net margin of 9.91%. The business had revenue of $712.03 million for the quarter, compared to analysts’ expectations of $660.51 million. On average, research analysts forecast that BioMarin Pharmaceutical will post 2.39 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Check Out Our Latest Stock Report on BioMarin Pharmaceutical
BioMarin Pharmaceutical Company Profile
BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.
Featured Stories
- Five stocks we like better than BioMarin Pharmaceutical
- How to buy stock: A step-by-step guide for beginners
- Why AutoZone Stock Could Be Your Next Top Performer
- 3 Healthcare Dividend Stocks to Buy
- Should You Invest in Treasury Bills?
- Stock Analyst Ratings and Canadian Analyst Ratings
- Analysts Think There’s Still Time to Get in on Edgewise, Up 332%
Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.